Trial Profile
A Phase 1/2, Safety Lead-in and Dose Expansion, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination With Nivolumab and Ipilimumab in Previously Treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Ivosidenib (Primary) ; Nivolumab (Primary)
- Indications Cholangiocarcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Servier
- 16 Nov 2023 Status changed from not yet recruiting to recruiting.
- 20 Oct 2023 Planned initiation date changed from 1 Sep 2023 to 23 Oct 2023.
- 19 Jul 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Mar 2026.